Dendreon Corp. said it would cut 500 jobs as it seeks to trim expenses in light of diminished sales expectations for its high-priced Provenge prostate cancer vaccine.
Dendreon to cut 500 jobs in restructuring
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.